Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Hematology

Advanced Risk Stratification: Understanding the IPSS-M

At a Glance

The IPSS-M is the newest and most accurate tool for predicting your myelodysplastic syndrome (MDS) prognosis. By analyzing 31 specific genes in your bone marrow alongside your blood counts, it provides a precise risk score to help your doctor choose the best treatment plan.

Prognosis in MDS is no longer just a “best guess” based on your age and blood counts. It is now a precise calculation that combines your clinical health with the unique “genetic fingerprint” of your bone marrow.

The newest and most accurate tool for this calculation is the Molecular International Prognostic Scoring System (IPSS-M) [1][2].

From IPSS-R to IPSS-M: Why the Update Matters

For years, the standard tool was the IPSS-R (Revised). It looked at three things: your blood counts, your blast percentage, and your chromosome structure [3]. While helpful, the IPSS-R was “blind” to the DNA mutations inside your cells.

The IPSS-M changes the game by adding a fourth pillar: Next-Generation Sequencing (NGS) data from 31 specific genes [1].

  • A Major Shift: When genetic data is added, nearly 46% of patients are reclassified into a different risk category [2]. Some move to a lower-risk group, while others are found to have higher-risk disease that requires more immediate action.
  • Precision: The IPSS-M provides a more accurate prediction of overall survival and leukemia-free survival (the time before the disease might turn into AML) [2][4].

The 31 Genes and “High-Stakes” Mutations

The IPSS-M integrates mutations from 31 genes, but they are not all equal. Some act as “accelerants” for the disease, while others are “stabilizers.”

  • The TP53 “Multi-Hit” Status: This is the most critical genetic marker in the system. A “multi-hit” (or biallelic) TP53 mutation is a very high-risk finding that often signals an aggressive disease course [2][5].
  • Favorable Markers: Mutations like SF3B1 (without other high-risk markers) are generally associated with a better prognosis and a slower disease course [2][6].
  • Adverse Markers: Mutations in genes like FLT3, MLL-PTD, or ASXL1 typically move a patient into a higher risk category [2][1].

Interpretation Guide: The Six Risk Categories

The IPSS-M places you into one of six categories. These categories help your doctor decide whether to “watch and wait” or move toward intensive treatments like a stem cell transplant [7].

Category Disease Tempo and Typical Approach
Very Low / Low Disease usually moves very slowly. Focus is heavily on symptom management and quality of life [8].
Moderate-Low Disease remains slow-moving but requires increased monitoring; treatment may be needed if counts drop [9].
Moderate-High Disease is moving faster. Doctors will transition toward active therapy to prevent progression [4].
High / Very High Disease is aggressive and moving quickly. Requires urgent evaluation for intensive therapies like transplant or clinical trials [10].

Limitations of the Model

While the IPSS-M is the best tool available, it is not perfect:

  1. A Snapshot in Time: The score is calculated at the time of your biopsy. MDS can change (evolve) over time, and a score from two years ago may no longer be accurate [11].
  2. Resource Dependent: Not every hospital has the equipment to test for all 31 genes. If your center only tests for 5 or 10 genes, your IPSS-M score might be missing critical data [12].
  3. Hereditary Gaps: Some rare mutations, such as DDX41 (which can be inherited), are not always perfectly captured by this general model [13].

Common questions in this guide

What is the difference between the IPSS-M and IPSS-R scores for MDS?
The older IPSS-R relies only on blood counts, blast percentages, and chromosome structure. The newer IPSS-M adds data from 31 specific genes, providing a much more accurate prediction of your prognosis and treatment needs.
What does a TP53 multi-hit mutation mean for my MDS prognosis?
A multi-hit TP53 mutation is a high-risk genetic marker. It typically indicates a more aggressive disease course and helps your doctor determine if intensive treatments are needed sooner.
Can my IPSS-M risk category change over time?
Yes. Your IPSS-M score is a snapshot taken at the time of your bone marrow biopsy. Because myelodysplastic syndrome can evolve, your doctor may need to re-test your molecular markers to ensure your treatment plan remains accurate.
What are the IPSS-M risk categories?
The IPSS-M divides patients into six categories ranging from Very Low to Very High risk. These categories help your care team decide whether to safely monitor your condition or move toward active therapies like a stem cell transplant.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my risk level been calculated using the IPSS-M (Molecular) score, or the older IPSS-R?
  2. 2.Which of the 31 genes in the IPSS-M panel were mutated in my case?
  3. 3.If I have a TP53 mutation, was it identified as 'multi-hit' or 'single-hit'? How does this specific result change my prognosis?
  4. 4.How does my risk category (e.g., Moderate-High or High) affect the timing of a potential stem cell transplant?
  5. 5.What are my specific odds for 'leukemia-free survival' over the next 2 to 5 years based on this score?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Risk prediction in MDS: independent validation of the IPSS-M-ready for routine?

    Baer C, Huber S, Hutter S, et al.

    Leukemia 2023; (37(4)):938-941 doi:10.1038/s41375-023-01831-1.

    PMID: 36725896
  2. 2

    Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

    Bernard E, Tuechler H, Greenberg PL, et al.

    NEJM evidence 2022; (1(7)):EVIDoa2200008 doi:10.1056/EVIDoa2200008.

    PMID: 38319256
  3. 3

    Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.

    Maggioni G, Della Porta MG

    Current opinion in hematology 2023; (30(2)):30-37 doi:10.1097/MOH.0000000000000752.

    PMID: 36728601
  4. 4

    Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

    Sauta E, Robin M, Bersanelli M, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(15)):2827-2842 doi:10.1200/JCO.22.01784.

    PMID: 36930857
  5. 5

    The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.

    Khanna V, Lu R, Kumar J, et al.

    Leukemia research 2024; (136()):107433 doi:10.1016/j.leukres.2023.107433.

    PMID: 38154193
  6. 6

    [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].

    Wang JY, Ma J, Lin YN, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2017; (38(3)):192-197 doi:10.3760/cma.j.issn.0253-2727.2017.03.004.

    PMID: 28395441
  7. 7

    Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.

    Lee WH, Tsai MT, Tsai XC, et al.

    Blood cancer journal 2023; (13(1)):120.

    PMID: 37558665
  8. 8

    Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials.

    Giesinger JM, La Nasa G, Sparano F, et al.

    Clinical practice and epidemiology in mental health : CP & EMH 2021; (17(1)):307-314 doi:10.2174/1745017902117010307.

    PMID: 35444708
  9. 9

    Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms.

    Badar T, Madanat YF, Zeidan AM

    Future oncology (London, England) 2023; (19(27)):1877-1889 doi:10.2217/fon-2023-0454.

    PMID: 37750305
  10. 10

    Myelodysplastic syndromes current treatment algorithm 2018.

    Steensma DP

    Blood cancer journal 2018; (8(5)):47 doi:10.1038/s41408-018-0085-4.

    PMID: 29795386
  11. 11

    Molecular monitoring of MDS: Watch this space!

    Scheid C

    British journal of haematology 2024; (205(3)):757-758 doi:10.1111/bjh.19644.

    PMID: 39039697
  12. 12

    Assessing the Relevance of Non-molecular Prognostic Systems for Myelodysplastic Syndrome in the Era of Next-Generation Sequencing.

    Lincango M, Andreoli V, Rivello HG, et al.

    Annals of laboratory medicine 2025; (45(1)):44-52 doi:10.3343/alm.2024.0089.

    PMID: 39054795
  13. 13

    Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.

    Makishima H, Saiki R, Nannya Y, et al.

    Blood 2023; (141(5)):534-549 doi:10.1182/blood.2022018221.

    PMID: 36322930

This page explains the IPSS-M risk scoring system for educational purposes only. Always consult your hematologist or oncologist to understand what your specific molecular score means for your prognosis and care plan.

Get notified when new evidence is published on Myelodysplastic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.